Powell N B, Riley R W, Troell R J, Li K, Blumen M B, Guilleminault C
Stanford University Sleep Disorders and Research Center, Calif, USA.
Chest. 1998 May;113(5):1163-74. doi: 10.1378/chest.113.5.1163.
To evaluate pain, swallowing, speech, edematous response, tissue shrinkage, sleep, snoring, and safety (energy limits and adverse effects) following radiofrequency (RF) treatment to the palate in 22 subjects with sleep-disordered breathing.
This investigation is a prospective nonrandomized study. Polysomnography, radiographic imaging, and infrared thermography, along with questionnaires and visual analog scales, were used to evaluate the effects of RF treatment to the palate.
Treatments were delivered on an outpatient basis at Stanford University Medical Center.
Twenty-two healthy patients (18 men), with a mean age of 45.3+/-9.1 years, were enrolled. All were snorers seeking treatment and met predetermined criteria: a respiratory disturbance index < or = 15, oxygen saturation > or = 85%, and a complaint of daytime sleepiness.
RF was delivered to the submucosa of the palate with a custom-fabricated electrode for a mean duration of 141+/-30 s with a mean of 3.6+/-1.2 treatments per patient. Reduction of their snoring scores determined the end point of the study.
Neither speech nor swallowing was adversely affected. Pain was of short duration (0 to 48 h) and was controlled with acetaminophen. There were no infections. Although there was documented edema at 24 to 48 h, there were no clinical airway compromises. Polysomnographic data showed improvement in esophageal pressure measurements of the mean nadir and the 95th percentile nadir (p=0.031, p=0.001) respectively, as well as the mean sleep efficiency index (p=0.002). Radiographic imaging showed a mean shrinkage of 5.5+/-3.7 mm (p< or =0.0001). Subjective snoring scores fell by a mean of 77% (8.3+/-1.8 to 1.9+/-1.7, p=0.0001) accompanied by improved mean Epworth sleepiness scores (8.5+/-4.4 to 5.2+/-3.3, p=0.0001).
The results of this investigation allowed the formulation of safety parameters for RF in this defined population with mild sleep-disordered breathing. There was a documented tissue reduction and improvement in symptoms in all subjects. However, given the small sample size and short-term follow-up, these results should be confirmed by further investigation.
评估22例睡眠呼吸紊乱患者在接受腭部射频(RF)治疗后的疼痛、吞咽、言语、水肿反应、组织收缩、睡眠、打鼾情况以及安全性(能量限制和不良反应)。
本研究为前瞻性非随机研究。采用多导睡眠图、影像学检查和红外热成像技术,同时结合问卷调查和视觉模拟量表来评估腭部RF治疗的效果。
治疗在斯坦福大学医学中心门诊进行。
招募了22例健康患者(18例男性),平均年龄为45.3±9.1岁。所有患者均为寻求治疗的打鼾者,且符合预定标准:呼吸紊乱指数≤15,氧饱和度≥85%,并有白天嗜睡的主诉。
使用定制电极将RF输送至腭部黏膜下层,平均持续时间为141±30秒,每位患者平均接受3.6±1.2次治疗。以打鼾评分降低作为研究终点。
言语和吞咽均未受到不利影响。疼痛持续时间较短(0至48小时),可用对乙酰氨基酚控制。未发生感染。尽管在24至48小时时有水肿记录,但未出现临床气道受压情况。多导睡眠图数据显示,食管压力测量的平均最低点和第95百分位数最低点分别有所改善(p = 0.031,p = 0.001),平均睡眠效率指数也有所改善(p = 0.002)。影像学检查显示平均收缩5.5±3.7毫米(p≤0.0001)。主观打鼾评分平均下降77%(从8.3±1.8降至1.9±1.7,p = 0.0001),同时Epworth嗜睡评分平均改善(从8.5±4.4降至5.2±3.3,p = 0.0001)。
本研究结果为在这一特定的轻度睡眠呼吸紊乱人群中应用RF制定了安全参数。所有受试者均有组织减少和症状改善的记录。然而,鉴于样本量小和随访时间短,这些结果应通过进一步研究加以证实。